{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030952","form_type":"8-K","ticker":"NSYS","cik":"0000722313","company_name":"NORTECH SYSTEMS INC","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.823173+00:00","generated_at":"2026-06-08T11:59:46.172021+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nortech Systems Q3 revenue down 5.4% to $33.4M; EPS $0.42 vs $0.53 prior; backlog $102M","bullets":["Revenue $33.4M, down 5.4% YoY; GAAP net income $1.2M ($0.42 diluted EPS) vs $1.5M ($0.53) in Q3 2022.","Gross margin 15.9%, up 30 bps from Q2 2023; EBITDA $1.6M flat with Q2 2023.","Backlog $102M at Sept 30, up slightly; YTD revenue $103.3M, up 4.8% from prior year.","Management cites two large customers pushing out orders; expects resolution near term.","Suzhou China facility earned Class II Medical Device certification from China NMPA, boosting medical sales in Asia."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030952","json":"https://secwatch.observer/filing/0001437749-23-030952.json","markdown":"https://secwatch.observer/filing/0001437749-23-030952.md","text":"https://secwatch.observer/filing/0001437749-23-030952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/722313/000143774923030952/0001437749-23-030952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/722313/000143774923030952/nsys20231108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T11:59:46.172021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2db1bdf7ea4cce9786dd9b709c91d5f07670fec1","claim":"NORTECH SYSTEMS INC reported third quarter ended September 30, 2023 results: revenue $33,369, net income $1,207, EPS $0.42 per diluted share.","evidence_excerpt":"across our medical, industrial and defense markets.” 2023 Third Quarter Results In $000, except EBITDA Q3 23 Q3 22 % Favorable YTD 2023 YTD 2022 % Favorable Revenue $33,369 $35,276 (5.4) % $103,278 $98,505 4.8% Gross Profit $5,319 $6,328 (16.0) % $16,277 $15,376 5.9% Operating Expenses $4,195 $4,383 4.3% $13,000 $12,237 (6.2) % Net Income $1,207","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/722313/000143774923030952/0001437749-23-030952-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$33,369"},{"label":"Net income","value":"$1,207"},{"label":"EPS","value":"$0.42 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}